Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Novartis
Novartis
Crossbow Therapeutics, Inc.
Solu Therapeutics, Inc
NextCure, Inc.
Prelude Therapeutics
Kahr Medical
Janssen Research & Development, LLC
Amgen
Foghorn Therapeutics Inc.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Novartis
Tr1X, Inc.
AbbVie
Epigenetix, Inc.
Takeda
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Hemavant Sciences GmbH
Guangzhou Lupeng Pharmaceutical Company LTD.
Prelude Therapeutics
Pfizer
Nanexa AB
Race Oncology Ltd
Biocity Biopharmaceutics Co., Ltd.
Prelude Therapeutics
Bayer
AstraZeneca
Novartis
Hutchmed
Humanigen, Inc.
Celgene
Celgene
Celgene
Boehringer Ingelheim
Boehringer Ingelheim
Prescient Therapeutics, Ltd.
JW Pharmaceutical
Erimos Pharmaceuticals
Celgene
Seagen Inc.
Daiichi Sankyo